

1. **External validation of a clinical prediction model in multiple sclerosis.** Moradi N, Sharmin S, Malpas CB, Shaygannejad V, Terzi M, Boz C, Yamout B, Khoury SJ, Turkoglu R, Karabudak R, Shalaby N, Soysal A, Altintas A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T. *Mult Scler.* 2022 Nov 30:13524585221136036. doi: 10.1177/13524585221136036. Epub ahead of print. PMID: 36448727.
2. **Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity.** Jokubaitis VG, Campagna MP, Ibrahim O, Stankovich J, Kleinova P, Matesanz F, Hui D, Eichau S, Slee M, Lechner-Scott J, Lea R, Kilpatrick TJ, Kalincik T, De Jager PL, Beecham A, McCauley JL, Taylor BV, Vucic S, Laverick L, Vodehnalova K, García-Sánchez MI, Alcina A, van der Walt A, Havrdova EK, Izquierdo G, Patsopoulos N, Horakova D, Butzkueven H. *Brain.* 2022 Nov 30:awac449. doi: 10.1093/brain/awac449. Epub ahead of print. PMID: 36448302.
3. **Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.** Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H. *Mult Scler.* 2022 Nov 26:13524585221137502. doi: 10.1177/13524585221137502. Epub ahead of print. PMID: 36433775.
4. **Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.** Simpson-Yap S, Pirmani A, Kalincik T, De Brouwer E, Geys L, Parciak T, Helme A, Rijke N, Hillert JA, Moreau Y, Edan G, Sharmin S, Spelman T, McBurney R, Schmidt H, Bergmann AB, Braune S, Stahmann A, Middleton RM, Salter A, Bebo B, Van der Walt A, Butzkueven H, Ozakbas S, Boz C, Karabudak R, Alroughani R, Rojas JI, van der Mei IA, Sciascia do Olival G, Magyari M, Alonso RN, Nicholas RS, Chertcoff AS, de Torres AZ, Arrambide G, Nag N, Descamps A, Costers L, Dobson R, Miller A, Rodrigues P, Prčkovska V, Comi G, Peeters LM. *Neurol Neuroimmunol Neuroinflamm.* 2022 Aug 29;9(6):e200021. doi: 10.1212/NXI.000000000200021. PMID: 36038263; PMCID: PMC9423711.
5. **Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.** Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S, Skibina O, Kuhle J, Hodgkinson S, Boz C, Alroughani R, Lechner-Scott J, Barnett M, Izquierdo G, Prat A, Horakova D, Kubala Havrdova E, Macdonell R, Patti F, Khoury SJ, Slee M, Karabudak R, Onofrj M, Van Pesch V, Prevost J, Monif M, Jokubaitis V, van der Walt A, Butzkueven H; MSBase Study Group. *J Neurol Neurosurg Psychiatry.* 2022 Oct 19:jnnp-2022-330104. doi: 10.1136/jnnp-2022-330104. Epub ahead of print. PMID: 36261289.
6. **Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.** Sharmin S, Malpas CB, Roos I, Diouf I, Alroughani R, Ozakbas S, Izquierdo G, Eichau S, Horakova D, Havrdova EK, Patti F, Terzi M, Boz C, Yamout B, Khoury SJ, Onofrj M, Lugaresi A, Altintas A, Prat A, Girard M, Duquette P, Sá MJ, La Spitaleri D, Sidhom Y, Gouider R, Mrabet S, Soysal A, Turkoglu R, Amato MP, Fragoso YD, Kalincik T. *J Neurol Neurosurg Psychiatry.* 2022 Sep 30: jnnp-2022-329713. doi: 10.1136/jnnp-2022-329713. Epub ahead of print. PMID: 36180218.

7. **Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.** Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, Hyde R, Pellegrini F, Magyari M, Koch-Henriksen N, Sørensen PS, Spelman T, van der Walt A, Horakova D, Havrdova E, Girard M, Eichau S, Grand'Maison F, Gerlach O, Terzi M, Ozakbas S, Skibina O, Van Pesch V, Sa MJ, Prevost J, Alroughani R, McCombe PA, Gouider R, Mrabet S, Castillo-Trivino T, Zhu C, de Gans K, Sánchez-Menoyo JL, Yamout B, Khoury S, Sormani MP, Kalincik T, Butzkueven H; Big MS Data Network. *J Neurol Neurosurg Psychiatry*. 2022 Sep 28; jnnp-2022-329987. doi: 10.1136/jnnp-2022-329987. Epub ahead of print. PMID: 36171104.
8. **Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.** Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, Moreau T, Amato MP, Labauge P, Alroughani R, Buzzard K, Skibina O, Terzi M, Laplaud DA, Berger E, Grand'Maison F, Lebrun-Frenay C, Cartechini E, Boz C, Lechner-Scott J, Clavelou P, Stankoff B, Prevost J, Kappos L, Pelletier J, Shaygannejad V, Yamout BI, Khoury SJ, Gerlach O, Spitaleri DLA, Van Pesch V, Gout O, Turkoglu R, Heinzlef O, Thouvenot E, McCombe PA, Soysal A, Bourre B, Slee M, Castillo-Trivino T, Bakchine S, Ampapa R, Butler EG, Wahab A, Macdonell RA, Aguera-Morales E, Cabre P, Ben NH, Van der Walt A, Laureys G, Van Hijfte L, Ramo-Tello CM, Maubeuge N, Hodgkinson S, Sánchez-Menoyo JL, Barnett MH, Labeyrie C, Vucic S, Sidhom Y, Gouider R, Csepany T, Sotoca J, de Gans K, Al-Asmi A, Fragoso YD, Vukusic S, Butzkueven H, Kalincik T; MSBase; OFSEP. *Neurology*. 2022 Aug 17;10.1212/WNL.000000000201029. doi: 10.1212/WNL.000000000201029. Epub ahead of print. PMID: 35977837.
9. **Prediction of multiple sclerosis outcomes when switching to ocrelizumab.** Zhong M, van der Walt A, Stankovich J, Kalincik T, Buzzard K, Skibina O, Boz C, Hodgkinson S, Slee M, Lechner-Scott J, Macdonell R, Prevost J, Kuhle J, Laureys G, Van Hijfte L, Alroughani R, Kermodé AG, Butler E, Barnett M, Eichau S, van Pesch V, Grammond P, McCombe P, Karabudak R, Duquette P, Girard M, Taylor B, Yeh W, Monif M, Gresle M, Butzkueven H, Jokubaitis VG. *Mult Scler*. 2022 May;28(6):958-969. doi: 10.1177/13524585211049986. Epub 2021 Oct 8. PMID: 34623947.
10. **Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.** Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Ben Nasr H, Hankiewicz K, Pottier C, Maubeuge N, Dimitri-Boulos D, Nifle C, Laplaud DA, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrij M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Karabudak R, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Koch-Henriksen N, Sellebjerg F, Soerensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, Leray E. *BMC Med Res Methodol*. 2022 May 30;22(1):155. doi: 10.1186/s12874-022-01623-8. PMID: 35637426; PMCID: PMC9150358.
11. **Confirmed disability progression as a marker of permanent disability in multiple sclerosis.** Sharmin S, Bovis F, Malpas C, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Trojano M, Prat A, Girard M, Duquette P, Onofrij M, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Terzi M, Gerlach O, Alroughani R, Boz C, Shaygannejad V, van Pesch V, Cartechini E, Kappos L, Lechner-Scott J, Bergamaschi R, Turkoglu R, Solaro C, Iuliano G, Granella F, Van Wijmeersch B, Spitaleri D, Slee M, McCombe P, Prevost J, Ampapa R,

Ozakbas S, Sanchez-Menoyo JL, Soysal A, Vucic S, Petersen T, de Gans K, Butler E, Hodgkinson S, Sidhom Y, Gouider R, Cristiano E, Castillo-Triviño T, Saladino ML, Barnett M, Moore F, Rozsa C, Yamout B, Skibina O, van der Walt A, Buzzard K, Gray O, Hughes S, Sempere AP, Singhal B, Fragoso Y, Shaw C, Kermodé A, Taylor B, Simo M, Shuey N, Al-Harbi T, Macdonell R, Dominguez JA, Csepany T, Sirbu CA, Sormani MP, Butzkueven H, Kalincik T. *Eur J Neurol.* 2022 May 18. doi: 10.1111/ene.15406. Epub ahead of print. PMID: 35582938.

12. ***Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.*** Vitkova M, Diouf I, Malpas C, Horakova D, Kubala Havrdova E, Patti F, Ozakbas S, Izquierdo G, Eichau S, Shaygannejad V, Onofrj M, Lugaresi A, Alroughani R, Prat A, Larochelle C, Girard M, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Butzkueven H, Buzzard K, Skibina O, Yamout BI, Karabudak R, Gerlach O, Lechner-Scott J, Maimone D, Bergamaschi R, Van Pesch V, Iuliano G, Cartechini E, José Sà M, Ampapa R, Barnett M, Hughes SE, Ramo-Tello CM, Hodgkinson S, Spitaleri DLA, Petersen T, Butler EG, Slee M, McGuigan C, McCombe PA, Granella F, Cristiano E, Prevost J, Taylor BV, Sánchez-Menoyo JL, Laureys G, Van Hijfte L, Vucic S, Macdonell RA, Gray O, Olascoaga J, Deri N, Fragoso YD, Shaw C, Kalincik T; MSBase Study Group. *Neurology.* 2022 Jun 14;98(24):e2401-e2412. doi: 10.1212/WNL.000000000200545. Epub 2022 Apr 11. PMID: 35410900; PMCID: PMC9231838.
13. ***Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.*** Kalincik T, Kister I, Bacon TE, Malpas CB, Sharmin S, Horakova D, Kubala-Havrdova E, Patti F, Izquierdo G, Eichau S, Ozakbas S, Onofrj M, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Boz C, Grand'Maison F, Bergamaschi R, Gerlach O, Sa MJ, Kappos L, Cartechini E, Lechner-Scott J, van Pesch V, Shaygannejad V, Granella F, Spitaleri D, Iuliano G, Maimone D, Prevost J, Soysal A, Turkoglu R, Ampapa R, Butzkueven H, Cutter G; for MSBase Study Group. *Mult Scler.* 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577. Epub ahead of print. PMID: 35373638.
14. ***Multiple Sclerosis Relapses Following Cessation of Fingolimod.*** Malpas CB, Roos I, Sharmin S, Buzzard K, Skibina O, Butzkueven H, Kappos L, Patti F, Alroughani R, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Hodgkinson S, Grammond P, Lechner-Scott J, Kalincik T; MSBase Study Group. *Clin Drug Investig.* 2022 Apr;42(4):355-364. doi: 10.1007/s40261-022-01129-7. Epub 2022 Mar 18. PMID: 35303292; PMCID: PMC8989797.
15. ***Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.*** Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand'Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H; MSBase Investigators. *Pharmacoeconomics.* 2022 Mar;40(3):323-339. doi: 10.1007/s40273-021-01106-6. Epub 2021 Dec 18. PMID: 34921350; PMCID: PMC8866337.
16. ***Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry.*** Kenney R, Liu M, Patil S, Alroughani R, Ampapa R, Bergamaschi R, Boz C, Butzkueven H, Gomez JC, Cartechini E, Madueño SE, Ferraro D, Grand-Maison F, Granella F, Horakova D, Izquierdo Ayuso G, Kalincik T, Lizrova Preiningerova J, Lugaresi A, Onofrj M, Ozakbas S, Patti F, Sola P, Soysal A, Spitaleri DLA, Terzi M, Turkoglu R, van Pesch V, Saidha S, Thorpe LE, Galetta SL, Balcer LJ, Kister I, Spelman T; MSBase Study Group. *J Neurol Sci.* 2021 Nov 15;430:118067. doi: 10.1016/j.jns.2021.118067. Epub 2021 Sep 3. PMID: 34537678.

17. **Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.** Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frénay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Laplaud D, Koch-Henriksen N, Sellebjerg FT, Soerensen PS, Pflieger CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Vukusic S, Butzkueven H, Kalincik T; Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators. *CNS Drugs*. 2021 Nov;**35(11):1217-1232**. doi: 10.1007/s40263-021-00860-7. Epub 2021 Sep 18. PMID: 34536228.
18. **Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.** Barnett M, Bergsland N, Weinstock-Guttman B, Butzkueven H, Kalincik T, Desmond P, Gaillard F, van Pesch V, Ozakbas S, Rojas JI, Boz C, Altintas A, Wang C, Dwyer MG, Yang S, Jakimovski D, Kyle K, Ramasamy DP, Zivadinov R. *Neuroimage Clin*. 2021;**32:102802**. doi: 10.1016/j.nicl.2021.102802. Epub 2021 Aug 24. PMID: 34469848; PMCID: PMC8408519.
19. **Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis.** Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, Madueño SE, Patti F, Edan G, Debouverie M, Pelletier J, Ozakbas S, Amato MP, Clavelou P, Grammond P, Boz C, Buzzard K, Skibina O, Ciron J, Gerlach O, Grand'Maison F, Lechner-Scott J, Malpas C, Butzkueven H, Vukusic S, Kalincik T; MSBase and OFSEP Study Groups. *Neurology*. 2021 Aug 31;**97(9):e869-e880**. doi: 10.1212/WNL.0000000000012354. Epub 2021 Jun 30. PMID: 34193589.
20. **Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018.** Moradi N, Sharmin S, Malpas C, Ozakbas S, Shaygannejad V, Terzi M, Boz C, Yamout B, Turkoglu R, Karabudak R, Hamdy S, Soysal A, Altıntaş A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T; MSBase Study Group. *CNS Drugs*. 2021 Oct;**35(10):1097-1106**. doi: 10.1007/s40263-021-00833-w. Epub 2021 Jun 23. PMID: 34164782.
21. **Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180].** De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrj M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, Sá MJ, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L. *Comput Methods Programs Biomed*. 2022 Jan;**213:106479**. doi: 10.1016/j.cmpb.2021.106479. Epub 2021 Nov 5. Erratum for: *Comput Methods Programs Biomed*. 2021 Sep;**208:106180**. PMID: 34749246.
22. **The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.** Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, Sellebjerg F, Sørensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand Maison F,

- Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Skibina O, Solaro C, Karabudak R, Wijmeersch BV, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, Sèze JD, Maillart E, Zephir H, Labauge P, Defer G, Lebrun C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Marousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Leray E, Laplaud DA, Butzkueven H, Kalincik T, Vukusic S, Magyari M. *Mult Scler Relat Disord*. 2021 Aug;53:103012. doi: 10.1016/j.msard.2021.103012. Epub 2021 May 8. PMID: 34116480.
23. ***The MSBase pregnancy, neonatal outcomes, and women's health registry.*** Jokubaitis VG, Skibina O, Alroughani R, Altintas A, Butzkueven H, Eichau S, Fragoso Y, Hellwig K, Hughes SE, Rath L, van der Walt A, Gray O. *Ther Adv Neurol Disord*. 2021 Apr 12;14:17562864211009104. doi: 10.1177/17562864211009104. PMID: 33912245; PMCID: PMC8047930.
24. ***Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.*** Yeh WZ, Widyastuti PA, Van der Walt A, Stankovich J, Havrdova E, Horakova D, Vodehnalova K, Ozakbas S, Eichau S, Duquette P, Kalincik T, Patti F, Boz C, Terzi M, Yamout B, Lechner-Scott J, Sola P, Skibina OG, Barnett M, Onofrj M, Sá MJ, McCombe PA, Grammond P, Ampapa R, Grand'Maison F, Bergamaschi R, Spitaleri DLA, Van Pesch V, Cartechini E, Hodgkinson S, Soysal A, Saiz A, Gresle M, Uher T, Maimone D, Turkoglu R, Hupperts RM, Amato MP, Granella F, Oreja-Guevara C, Altintas A, Macdonell RA, Castillo-Trivino T, Butzkueven H, Alroughani R, Jokubaitis VG; MSBase Study Group. *Neurology*. 2021 Apr 20;96(24):e2989–3002. doi: 10.1212/WNL.0000000000012084. Epub ahead of print. PMID: 33879599; PMCID: PMC8253565.
25. ***Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.*** Butzkueven H, Spelman T, Horakova D, Hughes S, Solaro C, Izquierdo G, Kubala Havrdová E, Grand'Maison F, Prat A, Girard M, Hupperts R, Onofrj M, Lugaresi A, Taylor B; MSBase Study Group, Giovannoni G, Kappos L, Hauser SL, Montalban X, Craveiro L, Freitas R, Model F, Overell J, Muros-Le Rouzic E, Sauter A, Wang Q, Wormser D, Wolinsky JS. *Eur J Neurol*. 2022 Apr;29(4):1082-1090. doi: 10.1111/ene.14824. Epub 2021 May 6. PMID: 33724638.
26. ***Determinants of therapeutic lag in multiple sclerosis.*** Roos I, Leray E, Frascoli F, Casey R, Brown JW, Horakova D, Havrdova EK, Debouverie M, Trojano M, Patti F, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grammond P, Ciron J, Ruet A, Ozakbas S, De Seze J, Louapre C, Zephir H, Sá MJ, Sola P, Ferraro D, Labauge P, Defer G, Bergamaschi R, Lebrun-Frenay C, Boz C, Cartechini E, Moreau T, Laplaud D, Lechner-Scott J, Grand'Maison F, Gerlach O, Terzi M, Granella F, Alroughani R, Iuliano G, Van Pesch V, Van Wijmeersch B, Spitaleri D, Soysal A, Berger E, Prevost J, Aguera-Morales E, McCombe P, Castillo Triviño T, Clavelou P, Pelletier J, Turkoglu R, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Sidhom Y, Gouider R, Csepany T, Bourre B, Al Khedr A, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanche JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Coles A, Malpas CB, Vukusic S, Butzkueven H, Kalincik T. *Mult Scler*. 2021 Oct;27(12):1838-1851. doi: 10.1177/1352458520981300. Epub 2021 Jan 11. PMID: 33423618.
27. ***Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.*** Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Jokubaitis V, van der Walt A, Grand'Maison F, Sola P, Ferraro D, Shaygannejad V, Alroughani R, Hupperts R, Terzi M, Boz C, Lechner-Scott J, Pucci E, Van Pesch V, Granella F, Bergamaschi R, Spitaleri D, Slee M, Vucic S, Ampapa R, McCombe P, Ramo-Tello C, Prevost J,

Olascoaga J, Cristiano E, Barnett M, Saladino ML, Sanchez-Menoyo JL, Hodgkinson S, Rozsa C, Hughes S, Moore F, Shaw C, Butler E, Skibina O, Gray O, Kermodé A, Csepány T, Singhal B, Shuey N, Piroška I, Taylor B, Simo M, Sirbu CA, Sas A, Butzkueven H; MSBase Study Group. *Neurology*. 2021 Feb 2;**96(5):e783-e797**. doi: [10.1212/WNL.00000000000011242](https://doi.org/10.1212/WNL.00000000000011242). Epub 2020 Dec 28. PMID: 33372028; PMCID: PMC7884998.

28. **Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.** Bovis F, Kalincik T, Lublin F, Cutter G, Malpas C, Horakova D, Havrdova EK, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Izquierdo G, Eichau S, Patti F, Terzi M, Grammond P, Bergamaschi R, Sola P, Ferraro D, Ozakbas S, Iuliano G, Boz C, Hupperts R, Grand'Maison F, Oreja-Guevara C, van Pesch V, Cartechini E, Petersen T, Altintas A, Soysal A, Ramo-Tello C, McCombe P, Turkoglu R, Butzkueven H, Wolinsky JS, Solaro C, Sormani MP. *Neurology*. 2021 Jan 12;**96(2):e214-e227**. doi: [10.1212/WNL.00000000000010991](https://doi.org/10.1212/WNL.00000000000010991). Epub 2020 Oct 6. PMID: 33024022; PMCID: PMC7905777.
29. **Delay from treatment start to full effect of immunotherapies for multiple sclerosis.** Roos I, Leray E, Frascoli F, Casey R, Brown JW, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Agüera-Morales E, Slee M, Csepány T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators. *Brain*. 2020 Sep 1;**143(9):2742-2756**. doi: [10.1093/brain/awaa231](https://doi.org/10.1093/brain/awaa231). PMID: 32947619.
30. **Association of Pregnancy With the Onset of Clinically Isolated Syndrome.** Nguyen AL, Vodehnalova K, Kalincik T, Signori A, Havrdova EK, Lechner-Scott J, Skibina OG, Eastaugh A, Taylor L, Baker J, McGuinn N, Rath L, Maltby V, Sormani MP, Butzkueven H, Van der Walt A, Horakova D, Jokubaitis VG. *JAMA Neurol*. 2020 Dec 1;**77(12):1496-1503**. doi: [10.1001/jamaneurol.2020.3324](https://doi.org/10.1001/jamaneurol.2020.3324). PMID: 32926074; PMCID: PMC7490748.
31. **Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.** Lizak N, Malpas CB, Sharmin S, Havrdova EK, Horakova D, Izquierdo G, Eichau S, Lugaresi A, Duquette P, Girard M, Prat A, Larochelle C, Trojano M, Grand'Maison F, Grammond P, Sola P, Ferraro D, Hupperts R, Bergamaschi R, Boz C, Van Pesch V, Spitaleri D, Terzi M, Kalincik T; MSBase Study Group. *JAMA Neurol*. 2020 Nov 1;**77(11):1398-1407**. doi: [10.1001/jamaneurol.2020.2453](https://doi.org/10.1001/jamaneurol.2020.2453). Erratum in: *JAMA Neurol*. 2021 Jan 1;**78(1):120**. PMID: 32716480; PMCID: PMC7385679.
32. **Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.** Kunchok A, Lechner-Scott J, Granella F, Trojano M, Alroughani R, Sola P, Ferraro D, Lugaresi A, Onofrj M, Ozakbas S, Izquierdo G, Grammond P, Luis Sanchez-Menoyo J, Van Wijmeersch B, Boz C, Pucci E, McCombe P, Grand'Maison F, Spitaleri D, Vucic S, Hupperts R, Jokubaitis V, Sormani MP, Butzkueven H, Kalincik T; MSBase Study Group. *Mult Scler*. 2021 Apr;**27(5):695-705**. doi: [10.1177/1352458520936823](https://doi.org/10.1177/1352458520936823). Epub 2020 Jul 8. PMID: 32639855.
33. **Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.** Le M, Malpas C, Sharmin S, Horáková D, Havrdova E, Trojano M, Izquierdo G, Eichau S, Ozakbas S, Lugaresi A, Prat A, Girard M, Duquette P, Larochelle C, Alroughani R, Bergamaschi R, Sola P, Ferraro D, Grammond P, Grand' Maison F, Terzi M, Boz C, Hupperts R, Butzkueven H, Pucci E, Granella F, Van Pesch V, Soysal A, Yamout BI, Lechner-Scott J, Spitaleri D, Ampapa R, Turkoglu R, Iuliano G, Ramo-Tello C, Sanchez-Menoyo JL, Sidhom Y, Gouider R, Shaygannejad V, Prevost J, Altintas A, Fragoso YD, McCombe PA, Petersen T, Slee M, Barnett MH, Vucic S, Van Der Walt A, Kalincik T. *Mult Scler*. 2021 Apr;**27(5):755-766**. doi: [10.1177/1352458520926955](https://doi.org/10.1177/1352458520926955). Epub 2020 Jun 15. PMID: 32538713.

34. **Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.** Lizak N, Hodgkinson S, Butler E, Lechner-Scott J, Slee M, McCombe PA, Shaw C, Skibina O, Vucic S, Shuey N, Barnett MH, Parratt J, Butzkueven H, Jack D, Fabris J, Kalincik T. *Mult Scler.* 2021 Mar;27(3):465-474. doi: 10.1177/1352458520921087. Epub 2020 Jun 12. PMID: 32530363; PMCID: PMC7897790.
35. **Early clinical markers of aggressive multiple sclerosis.** Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Eichau S, Bergamaschi R, Sola P, Ferraro D, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Grand'Maison F, Ozakbas S, Van Pesch V, Granella F, Hupperts R, Pucci E, Boz C, Sidhom Y, Gouider R, Spitaleri D, Soysal A, Petersen T, Verheul F, Karabudak R, Turkoglu R, Ramo-Tello C, Terzi M, Cristiano E, Slee M, McCombe P, Macdonell R, Fragoso Y, Olascoaga J, Altintas A, Olsson T, Butzkueven H, Hillert J, Kalincik T. *Brain.* 2020 May 1;143(5):1400-1413. doi: 10.1093/brain/awaa081. PMID: 32386427.
36. **Timing of high-efficacy therapy for multiple sclerosis: a retrospective observation cohort study.** He A, Merkel B, Brown JW, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand'Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T; MSBase study group. *Lancet Neurol.* 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18. PMID: 32199096.
37. **Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.** Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand'Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrij M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T. *Mult Scler Relat Disord.* 2020 Feb;38:101868. doi: 10.1016/j.msard.2019.101868. Epub 2019 Nov 25. PMID: 31877445.
38. **Risk of secondary progressive multiple sclerosis: A longitudinal study.** Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T. *Mult Scler.* 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9. PMID: 31397221.
39. **The MSBase Registry: Informing Clinical Practice.** Kalincik T, Butzkueven H. *Mult Scler.* 2019 Dec;25(14):1828-1834. doi: 10.1177/1352458519848965. Epub 2019 May 23. PMID: 31120376.
40. **Comparison of fingolimod, dimethyl fumarate and teriflunomide for Multiple Sclerosis.** Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrij M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL,

Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. *J Neurol Neurosurg Psychiatry*. 2019 Apr;**90(4)**:458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13. PMID: 30636699.

41. ***Incidence of pregnancy and disease-modifying therapy exposure trends in women with Multiple Sclerosis: A contemporary cohort study.*** Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group. *Mult Scler Relat Disord*. 2019 Feb;**28**:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3. PMID: 30623864.
42. ***Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.*** Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group. *Eur J Neurol*. 2019 Feb;**26(2)**:363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2. Erratum in: *Eur J Neurol*. 2020 Jun;**27(6)**:1096. PMID: 30298572.
43. ***Association of Initial Disease-Modifying Therapy with later conversion to Secondary Progressive Multiple Sclerosis.*** Brown JW, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. *JAMA*. 2019 Jan **15**;321(2):175-187. doi: 10.1001/jama.2018.20588. Erratum in: *JAMA*. 2020 Apr **7**;323(13):1318. PMID: 30644981; PMCID: PMC6439772.
44. ***Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis.*** Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group. *JAMA Neurol*. 2018 Nov **1**;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109. PMID: 30083762; PMCID: PMC6248114.
45. ***Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis.*** Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J. *Mult Scler*. 2018 Oct;**24(12)**:1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20. PMID: 30234431.
46. ***Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.*** Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermodé A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group. *Mult Scler*. 2018 Oct;**24(12)**:1617-1626. doi: 10.1177/1352458517728812. Epub 2017 Aug 31. Erratum in: *Mult Scler*. 2017 Dec;**23(14)**:NP1. PMID: 28857680.

47. **Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.** Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H. *J Neurol Sci.* 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2. PMID: 30103975.
48. **Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.** Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M. *Mult Scler.* 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6. PMID: 28382837.
49. **Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.** Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Sánchez-Menoyo JL, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators. *Mult Scler Relat Disord.* 2018 Jan;19:105-108. doi: 10.1016/j.msard.2017.11.018. Epub 2017 Nov 22. PMID: 29182993.
50. **Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.** Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group. *Brain.* 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185. PMID: 29050389.
51. **Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.** Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group. *Neurology.* 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9. PMID: 28794248; PMCID: PMC5589791.
52. **Quantifying risk of early relapse in patients with demyelinating events: Prediction in clinical practice.** Spelman T, Meyniel C, Rojas JI, Lugaresi A, Izquierdo G, Grand'Maison F, Boz C, Alroughani R, Havrdova E, Horakova D, Iuliano G, Duquette P, Terzi M, Grammond P, Hupperts R, Lechner-Scott J, Oreja-Guevara C, Pucci E, Verheul F, Fiol M, Van Pesch V, Cristiano E, Petersen T, Moore F, Kalincik T, Jokubaitis V, Trojano M, Butzkueven H; MSBasis (an MSBase Substudy) Investigators. *Mult Scler.* 2017 Sep;23(10):1346-1357. doi: 10.1177/1352458516679893. Epub 2016 Nov 25. PMID: 27885062.
53. **Incidence and prevalence of NMOSD in Australia and New Zealand.** Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das

- C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermodé AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA. *J Neurol Neurosurg Psychiatry*. 2017 Aug;**88(8)**:632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26. PMID: 28550069.
54. ***Prognostic indicators in pediatric clinically isolated syndrome.*** Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. *Ann Neurol*. 2017 May;**81(5)**:729-739. doi: 10.1002/ana.24938. PMID: 28439957.
55. ***Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.*** Kalincik T, Brown JW, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group. *Lancet Neurol*. 2017 Apr;**16(4)**:271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11. PMID: 28209331.
56. ***Data quality evaluation for observational multiple sclerosis registries.*** Kalincik T, Kuhle J, Pucci E, Rojas JJ, Tsolaki M, Sirbu CA, Slee M, Butzkueven H; MSBase Scientific Leadership Group and MSBase Study Group. *Mult Scler*. 2017 Apr;**23(5)**:647-655. doi: 10.1177/1352458516662728. Epub 2016 Aug 5. PMID: 27481209.
57. ***Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.*** Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Grammond P, Hupperts R, Grand'Maison F, Sola P, Pucci E, Bergamaschi R, Oreja-Guevara C, Van Pesch V, Ramo C, Spitaleri D, Iuliano G, Boz C, Granella F, Olascoaga J, Verheul F, Rozsa C, Cristiano E, Flechter S, Hodgkinson S, Amato MP, Deri N, Jokubaitis V, Spelman T, Butzkueven H, Kalincik T; MSBase Study Group. *J Neurol Neurosurg Psychiatry*. 2017 Mar;**88(3)**:196-203. doi: 10.1136/jnnp-2016-313976. Epub 2016 Sep 28. PMID: 27683916.
58. ***Contribution of different relapse phenotypes to disability in multiple sclerosis.*** Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermodé A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group. *Mult Scler*. 2017 Feb;**23(2)**:266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11. PMID: 27055805.
59. ***Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.*** Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S,

Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group. *J Neurol Neurosurg Psychiatry*. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3. PMID: 27810919.

60. ***Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.*** Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand'Maison F, Slee M, Lugaresi A, Barnett M, Grammond P, Iuliano G, Hupperts R, Pucci E, Trojano M, Butzkueven H; MSBase Study Group. *J Neurol Neurosurg Psychiatry*. 2016 Oct;87(10):1133-7. doi: 10.1136/jnnp-2016-313760. Epub 2016 Jun 13. Erratum in: *J Neurol Neurosurg Psychiatry*. 2019 Apr;90(4):e2. PMID: 27298148.
61. ***Defining secondary progressive multiple sclerosis.*** Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group. *Brain*. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7. PMID: 27401521.
62. ***Predictors of long-term disability accrual in relapse-onset multiple sclerosis.*** Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M; MSBase Study Group. *Ann Neurol*. 2016 Jul;80(1):89-100. doi: 10.1002/ana.24682. Epub 2016 Jun 1. PMID: 27145331.
63. ***Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.*** Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H. *Neurol Clin Pract*. 2016 Apr;6(2):102-115. doi: 10.1212/CPJ.0000000000000227. PMID: 27104064; PMCID: PMC4828679.
64. ***Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.*** Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'Maison F, Grammond P, Barnett M, Lechner-Scott J, Alroughani R, Trojano M, Lugaresi A, Granella F, Pucci E, Vucic S; MSBase Study Group. *Eur J Neurol*. 2016 Apr;23(4):729-36. doi: 10.1111/ene.12929. Epub 2016 Jan 19. PMID: 26782663.
65. ***The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.*** Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, Alroughani R, Iuliano G, Duquette P, Girard M, Terzi M, Hupperts R, Grammond P, Petersen T, Fernandez-Bolaños R, Fiol M, Pucci E, Lechner-Scott J, Verheul F, Cristiano E, Van Pesch V, Petkovska-Boskova T, Moore F, Kister I, Bergamaschi R, Saladino ML, Slee M, Barnett M, Amato MP, Shaw C, Shuey N, Young C, Gray O, Kappos L, Butzkueven H, Kalincik T, Jokubaitis V; MSBase study group. *Mult Scler*. 2016 Apr;22(4):520-32. doi: 10.1177/1352458515594041. Epub 2015 Jul 21. PMID: 26199347.
66. ***Defining reliable disability outcomes in multiple sclerosis.*** Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, Lechner-Scott J, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolaños R, Ramo C, Terzi M, Slee M, Spitaleri D, Verheul F, Cristiano E,

Sánchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H. *Brain*. 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10. PMID: 26359291.

67. **Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.** Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, Grand'Maison F, Pucci E, Van Pesch V, Boz C, Iuliano G, Fernandez-Bolanos R, Flechter S, Spitaleri D, Cristiano E, Verheul F, Lechner-Scott J, Amato MP, Cabrera-Gomez JA, Saladino ML, Slee M, Moore F, Gray O, Paine M, Barnett M, Havrdova E, Horakova D, Spelman T, Trojano M, Butzkueven H; MSBase Study Group. *Mult Scler*. 2015 Aug;21(9):1159-71. doi: 10.1177/1352458514559865. Epub 2014 Dec 5. PMID: 25480857.
68. **Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry.** Rojas JI, Patrucco L, Trojano M, Lugaresi A, Izquierdo G, Butzkueven H, Jokubaitis V, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Petersen T, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Rio ME, Van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Fernandez-Bolanos R, Poehlau D, Saladino ML, Braber-Moerland LD, Deri N, Oleschko-Arruda W, Cabrera-Gomez JA, Paine M, Vella N, Kister I, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, Bacile EAB, Santiago V, Cristiano E. *Mult Scler J Exp Transl Clin*. 2015 Aug 17;1:2055217315600193. doi: 10.1177/2055217315600193. PMID: 28607702; PMCID: PMC5408755.
69. **Male Sex is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.** Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Hupperts R, Grammond P, Oreja-Guevara C, Petersen T, Bergamaschi R, Giuliani G, Barnett M, van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Cristiano E, Fernandez-Bolanos R, Saladino ML, Rio ME, Cabrera-Gomez J, Butzkueven H, van Munster E, Den Braber-Moerland L, La Spitaleri D, Lugaresi A, Shaygannejad V, Gray O, Deri N, Alroughani R, Lechner-Scott J. *PLoS One*. 2015 Jun 5;10(6):e0122686. doi: 10.1371/journal.pone.0122686. PMID: 26046348; PMCID: PMC4457630.
70. **BREMSO: a simple score to predict early the natural course of multiple sclerosis.** Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, Grand'Maison F, Duquette P, Shaygannejad V, Alroughani R, Grammond P, Boz C, Iuliano G, Zwanikken C, Petersen T, Lechner-Scott J, Hupperts R, Butzkueven H, Pucci E, Oreja-Guevara C, Cristiano E, Pia Amato MP, Havrdova E, Fernandez-Bolanos R, Spelman T, Trojano M. *Eur J Neurol*. 2015 Jun;22(6):981-9. doi: 10.1111/ene.12696. Epub 2015 Mar 25. PMID: 25808578.
71. **Predictors of disability worsening in clinically isolated syndrome.** Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand'Maison F, Duquette P, Girard M, Lugaresi A, Grammond P, Hupperts R, Cabrera-Gomez J, Oreja-Guevara C, Boz C, Giuliani G, Fernández-Bolaños R, Iuliano G, Lechner-Scott J, Verheul F, van Pesch V, Petkovska-Boskova T, Fiol M, Moore F, Cristiano E, Alroughani R, Bergamaschi R, Barnett M, Slee M, Vella N, Herbert J, Shaw C, Saladino ML, Amato MP, Liew D, Paolicelli D, Butzkueven H, Trojano M. *Ann Clin Transl Neurol*. 2015 May;2(5):479-91. doi: 10.1002/acn3.187. Epub 2015 Mar 27. PMID: 26000321; PMCID: PMC4435703.
72. **Comparative efficacy of switching to natalizumab in active multiple sclerosis.** Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, Grand-Maison F, Izquierdo G, Grammond P, Duquette P, Lugaresi A, Lechner-Scott J, Oreja-Guevara C, Hupperts R, Petersen T, Barnett M, Trojano M, Butzkueven H. *Ann Clin Transl Neurol*. 2015 Apr;2(4):373-87. doi: 10.1002/acn3.180. Epub 2015 Feb 27. PMID: 25909083; PMCID: PMC4402083.
73. **Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.** He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-

Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group. *JAMA Neurol.* 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. Erratum in: *JAMA Neurol.* 2015 Aug;72(8):950. PMID: 25665031.

74. **Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.** Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugesesi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group. *Ann Neurol.* 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17. PMID: 25546031.
75. **Seasonal variation of relapse rate in multiple sclerosis is latitude-dependent.** Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugesesi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand'Maison F, Edite Rio M, Lechner-Scott J, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H. *Ann Neurol.* 2014 Dec;76(6):880-90. doi: 10.1002/ana.24287. Epub 2014 Oct 20. PMID: 25283272.
76. **Risk of relapse phenotype recurrence in multiple sclerosis.** Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G, Girard M, Lugesesi A, Grammond P, Grand'Maison F, Oreja-Guevara C, Boz C, Hupperts R, Petersen T, Giuliani G, Iuliano G, Lechner-Scott J, Barnett M, Bergamaschi R, Van Pesch V, Amato MP, van Munster E, Fernandez-Bolanos R, Verheul F, Fiol M, Cristiano E, Slee M, Rio ME, Spitaleri D, Alroughani R, Gray O, Saladino ML, Flechter S, Herbert J, Cabrera-Gomez JA, Vella N, Paine M, Shaw C, Moore F, Vucic S, Savino A, Singhal B, Petkovska-Boskova T, Parratt J, Sirbu CA, Rozsa C, Liew D, Butzkueven H; MSBase Study Group. *Mult Scler.* 2014 Oct;20(11):1511-22. doi: 10.1177/1352458514528762. Epub 2014 Apr 28. PMID: 24777276.
77. **Predictors and dynamics of postpartum relapses in women with multiple sclerosis.** Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugesesi A, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Edite Rio M, van Pesch V, Amato MP, Iuliano G, Slee M, Verheul F, Cristiano E, Fernández-Bolaños R, Poehlau D, Saladino ML, Deri N, Cabrera-Gomez J, Vella N, Herbert J, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, McDonnell G, Hawkins S, Kee F, Butzkueven H; MSBase study group. *Mult Scler.* 2014 May;20(6):739-46. doi: 10.1177/1352458513507816. Epub 2013 Oct 9. PMID: 24107309.
78. **Fingolimod after natalizumab and the risk of short-term relapse.** Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugesesi A, Duquette P, Girard M, Barnett M, Grand'Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven H; MSBase Study Group. *Neurology.* 2014 Apr 8;82(14):1204-11. doi: 10.1212/WNL.000000000000283. Epub 2014 Mar 7. PMID: 24610329; PMCID: PMC4001200.
79. **Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.** Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugesesi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group. *Brain.* 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18. PMID: 24142147.

80. **Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.** Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, Van Pesch V, Grand'maison F, La Spitaleri D, Rio ME, Flechter S, Oreja-Guevara C, Giuliani G, Savino A, Amato MP, Petersen T, Fernandez-Bolanos R, Bergamaschi R, Iuliano G, Boz C, Lechner-Scott J, Deri N, Gray O, Verheul F, Fiol M, Barnett M, van Munster E, Santiago V, Moore F, Slee M, Saladino ML, Alroughani R, Shaw C, Kasa K, Petkovska-Boskova T, den Braber-Moerland L, Chapman J, Skromne E, Herbert J, Poehlau D, Needham M, Bacile EA, Arruda WO, Paine M, Singhal B, Vucic S, Cabrera-Gomez JA, Butzkueven H; MSBase Study Group. *PLoS One*. 2013 May 21;8(5):e63480. doi: 10.1371/journal.pone.0063480. PMID: 23704913; PMCID: PMC3660604.
81. **Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study.** Iuliano G, Boz C, Cristiano E, Duquette P, Lugaresi A, Oreja-Guevara C, Van Pesch V. *J Neurol*. 2013 May;260(5):1258-62. doi: 10.1007/s00415-012-6785-y. Epub 2012 Dec 21. PMID: 23263474.
82. **Fluctuations of MS births and UV-light exposure.** Verheul F, Smolders J, Trojano M, Lepore V, Zwanikken C, Amato MP, Grand'maison F, Butzkueven H, Marrosu M, Duquette P, Comi G, Izquierdo G, Grammond P, Lus G, Petersen T, Bergamaschi R, Giuliani G, Boz C, Coniglio G, Van Pesch V, Lechner-Scott J, Cavalla P, Granella F, Avolio C, Fiol M, Poehlau D, Saladino ML, Gallo P, Deri N, Oleschko Arruda W, Paine M, Ferro M, Barnett M, Cabrera-Gomez JA, Slee M, Moore F, Shaw C, Petkovska-Boskova T, Rutherford M, Engelsen O, Damoiseaux J, Hupperts R. *Acta Neurol Scand*. 2013 May;127(5):301-8. doi: 10.1111/ane.12007. Epub 2012 Sep 12. PMID: 22970985.
83. **The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform.** Jokubaitis, V. G., T. Spelman, J. Lechner-Scott, M. Barnett, C. Shaw, S. Vucic, D. Liew, H. Butzkueven, M. Slee, on behalf of the Australian MSBase Study Group. *PLoS One* (Mar 2013) 8(3):e59694. <http://dx.doi.org/10.1371/journal.pone.0059694>
84. **Geographical variations in sex ratio trends over time in multiple sclerosis.** Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Drenzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group. *PLoS One*. 2012;7(10):e48078. doi: 10.1371/journal.pone.0048078. Epub 2012 Oct 25. PMID: 23133550; PMCID: PMC3485003.
85. **Increasing age at disability milestones among MS patients in the MSBase registry.** Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand'Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J; MSBase Investigators. *J Neurol Sci*. 2012 Jul 15;318(1-2):94-9. doi: 10.1016/j.jns.2012.03.017. Epub 2012 Apr 14. PMID: 22507751.
86. **The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude.** Lechner-Scott J, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, Grand'Maison F, Gomez JA, Izquierdo G, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Boz C, Giuliani G, van Pesch V, Iuliano G, Fiol M, Cristiano E, Verheul F, Saladino ML, Slee M, Barnett M, Deri N, Flechter S, Vella N, Shaw C, Herbert J, Moore F, Petkovska-Boskova T, Jokubaitis V, Butzkueven H; MSBase study group. *Mult Scler*. 2012 Jul;18(7):974-82. doi: 10.1177/1352458511431729. Epub 2011 Dec 20. PMID: 22185806.
87. **Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.** Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'Maison F, Oreja-Guevara C, Boz C, Lugaresi A, Girard M, Grammond P, Iuliano G, Fiol M,

Cabrera-Gomez JA, Fernandez-Bolanos R, Giuliani G, Lechner-Scott J, Cristiano E, Herbert J, Petkovska-Boskova T, Bergamaschi R, van Pesch V, Moore F, Vella N, Slee M, Santiago V, Barnett M, Havrdova E, Young C, Sirbu CA, Tanner M, Rutherford M, Butzkueven H; MSBasis Study Group. *PLoS One*. 2012;7(6):e38661. doi: 10.1371/journal.pone.0038661. Epub 2012 Jun 29. PMID: 22768046; PMCID: PMC3387159.

88. ***The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase registry.*** Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group. *J Neurol Neurosurg Psychiatry*. 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28. PMID: 22205675.
89. ***MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.*** Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski JP. *Mult Scler*. 2006 Dec;12(6):769-74. doi: 10.1177/1352458506070775. PMID: 17263005.